Incyte Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. Incyte is a biopharmaceutical company with commercial products and development programs in hematology/oncology and inflammation/autoimmunity. It reports as one operating segment.
Financial performance and liquidity
- Revenue: $880.9 million, up 8.9% from $808.7 million. Product revenue was $729.9 million (+5.3%); royalty revenue was $126.0 million (+9.1%); milestone and contract revenue was $25.0 million, versus none in Q1 2023.
- Product trends: JAKAFI revenue declined to $571.8 million from $580.0 million, primarily reflecting lower channel inventory. OPZELURA grew to $85.7 million from $56.6 million, driven by new patient starts and refills. MINJUVI/MONJUVI revenue rose to $23.9 million from $6.6 million; the quarter included the February acquisition of global tafasitamab rights.
- Profitability: Operating income was $91.9 million, versus $24.8 million. Net income was $169.5 million, versus $21.7 million; diluted EPS was $0.75, versus $0.10. The comparison is materially affected by a $99.9 million unrealized gain on long-term investments in Q1 2024, versus a $5.3 million loss in Q1 2023. The filing does not provide a standalone gross-margin percentage.
- Expenses and taxes: R&D expense increased to $429.3 million from $406.6 million, mainly due to salary and benefits. SG&A declined to $300.3 million from $315.6 million, primarily due to the timing of marketing and other costs. The effective tax rate was 28.2%, down from 58.1%.
- Cash flow: Operating activities provided $218.8 million, compared with $105.6 million used in Q1 2023; management attributed the improvement primarily to working-capital changes. Investing activities used $73.1 million and financing activities used $12.4 million. Cash, cash equivalents and restricted cash increased by $132.6 million to $3.35 billion.
- Liquidity and debt: Cash, cash equivalents and marketable securities totaled approximately $3.85 billion at March 31. The $500 million revolving credit facility had no outstanding borrowings, and Incyte reported covenant compliance. Management stated available resources and operating cash flow should meet capital needs for the foreseeable future.
- Balance sheet: Total assets were $7.14 billion and total liabilities were $1.74 billion. Inventory was $327.9 million, including $264.3 million classified as non-current.
Material changes and developments
- In February, Incyte paid MorphoSys $25.0 million for exclusive global tafasitamab rights and MONJUVI inventory, ending the prior collaboration. Incyte now recognizes U.S. commercialization and clinical-development revenue and costs. The agreement makes Incyte responsible for potential payments to Xencor, including up to $186.5 million in development and regulatory milestones, up to $50.0 million in sales milestones, and tiered royalties.
- In March, Incyte recognized $25.0 million of upfront revenue from a povorcitinib license to China Medical Systems for certain Asian territories; additional milestones and royalties may be payable to Incyte.
- Long-term investments increased to $287.7 million from $187.7 million at year-end. Their unrealized gains significantly boosted reported Q1 earnings and may fluctuate with investee share prices.
- In April, after quarter-end, Incyte agreed to acquire Escient Pharmaceuticals for $750.0 million plus its net cash at closing, subject to adjustments, regulatory clearance and other customary conditions.
Outlook, risks and contingencies
- The filing provides no quantitative revenue or earnings guidance. Management expects available cash, operating cash flow and the undrawn credit facility to be adequate for foreseeable capital needs.
- Incyte’s CMS lawsuit challenges treatment of OPZELURA as a JAKAFI “line extension” under Medicaid rebates. It accrued approximately $73.7 million for potential incremental rebates; the estimated Q1 impact on OPZELURA gross-to-net deductions was 7.2%. A favorable outcome could reverse the accrual; the timing and outcome are uncertain.
- A contractual dispute with Novartis concerns U.S. JAKAFI royalties. Accrued royalties dependent on the dispute’s outcome were $398.6 million at March 31, 2024. This is an accrued liability, not a stated final settlement amount.
- Key business risks include reliance on JAKAFI, pricing and reimbursement pressure, concentration among specialty pharmacies and wholesalers, clinical and regulatory uncertainty, competition and generic challenges, and reliance on third-party manufacturers and collaborators. Incyte also notes supplier concentration for some inventory components.
- Axatilimab’s BLA for chronic GVHD was under FDA priority review; timing and approval are uncertain. The filing also describes ongoing clinical programs and regulatory risks, but does not provide financial guidance tied to those programs.
Most important facts for investors to verify
- How much of earnings growth reflects recurring operations versus the $99.9 million unrealized investment gain.
- Whether JAKAFI’s revenue decline persists and OPZELURA’s growth converts into sustainable net revenue after rebates and other deductions.
- Developments and potential cash consequences in the CMS and Novartis disputes, including the related accruals.
- Progress, review timing and outcome for axatilimab, and the costs, conditions and integration implications of the proposed Escient acquisition.
- Inventory recoverability and supply resilience, alongside the continued absence of borrowings under the revolving facility.